Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 3, 2013, Pages

  Marchbank, Tania ^a,b   Mahmood, Asif ^c   Playford, Raymond J ^a  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cellular invasion; Repair; Restitution; Tumor associated trypsin inhibitor

Indexed keywords

AKT3 PROTEIN; APROTININ; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; PROTEIN KINASE B BETA; S6 KINASE; SOYBEAN TRYPSIN INHIBITOR; TRYPSIN INHIBITOR; TYRPHOSTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOCRINE EFFECT; BLADDER CANCER; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

EID: 84881010672     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00357.2012     Document Type: Article

References (30)

1. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ. Overexpression of AKT2/protein kinase B leads to up-regulation of 1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63: 196-206, 2003.
2. Chen JM, Mercier B, Audrezet MP, Raguenes O, Quere I, Ferec C. Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis. Gastroenterology 120: 1061-1064, 2001.
3. Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther 319: 533-542, 2006.
4. Diggle CP, Cruickshank S, Olsburgh JD, Pellegrin S, Smith B, Banks RE, Selby PJ, Knowles MA, Southgate J, Harnden P. Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol 163: 493-504, 2003.
5. Dillon RL, Muller WJ. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 70: 4260-4264, 2010.
6. Elliott AY, Cleveland P, Cervenka J, Castro AE, Stein N, Hakala TR, Fraley EE. Characterization of a cell line from human transitional cell cancer of the urinary tract. J Natl Cancer Inst 53: 1341-1349, 1974.
7. Freeman TC, Curry BJ, Calam J, Woodburn JR. Pancreatic secretory trypsin inhibitor stimulates the growth of rat pancreatic carcinoma cells. Gastroenterology 99: 1414-1420, 1990.
8. Fukayama M, Hayashi Y, Koike M, Ogawa M, Kosaki G. Immuno-histochemical localization of pancreatic secretory trypsin inhibitor in fetal and adult pancreatic and extrapancreatic tissues. J Histochem Cytochem 34: 227-235, 1986.
9. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, McNeish JD, Coleman KG. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB. J Clin Invest 112: 197-208, 2003.
10. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 8: 2502-2508, 2009.
11. Huhtala ML, Kahanpää K, Seppälä M, Halila H, Stenman UH. Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer 31: 711-714, 1983.
12. Kelloniemi E, Rintala E, Finne P, Stenman UH. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 62: 249-253, 2003.
13. Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS, Chung J. Akt/PKB promotes cancer cell invasion via increased motility and metal-loproteinase production. FASEB J 15: 1953-62, 2001.
14. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recur-rence and a stage-independent prognostic factor of hepatocellular carci-noma. Eur J Cancer 43: 736-44, 2007.
15. Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58: 621-631, 2006.
16. Marchbank T, Chinery R, Hanby AM, Poulsom R, Elia G, Playford RJ. Distribution and expression of pancreatic secretory trypsin inhibitor and its possible role in epithelial restitution. Am J Pathol 148: 715-722, 1996.
17. Marchbank T, Freeman TC, Playford RJ. Human pancreatic secretory trypsin inhibitor. Distribution, actions and possible role in mucosal integ-rity and repair. Digestion 59: 167-174, 1998.
18. Marchbank T, Mahmood A, Fitzgerald AJ, Domin J, Butler M, Goodlad RA, Elia G, Cox HM, van Heel DA, Ghosh S, Playford RJ. Human pancreatic secretory trypsin inhibitor stabilizes intestinal mucosa against noxious agents. Am J Pathol 171: 1462-1473, 2007.
19. Marchbank T, Weaver G, Nilsen-Hamilton M, Playford RJ. Pancreatic secretory trypsin inhibitor is a major motogenic and protective factor in human breast milk. Am J Physiol Gastrointest Liver Physiol 296: G697-G703, 2009.
20. Nakayama GR, Caton MC, Nova MP, Parandoosh Z. Assessment of the alamarBlue assay for cellular growth and viability in vitro. J Immunol 204: 205-208, 1997.
21. Nathan JD, Romac J, Peng RY, Peyton M, Rockey Liddle DC, RA. Protection against chronic pancreatitis and pancreatic fibrosis in mice overexpressing pancreatic secretory trypsin inhibitor. Pancreas 39: 24-30, 2010.
22. Niinobu T, Ogawa M, Shibata T, Murata A, Nishibe S, Mori T, Ogata N. Specific binding of human pancreatic secretory trypsin inhibitor to various cultured cells. Res Commun Chem Pathol Pharmacol 53: 245-248, 1986.
23. Niinobu T, Ogawa M, Murata A, Nishijima J, Mori T. Identification and characterization of receptors specific for human pancreatic secretory trypsin inhibitor. J Exp Med 172: 1133-1142, 1990.
24. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J 392: 249-261, 2005.
25. Playford RJ, Marchbank T, Chinery R, Evison R, Pignatelli M, Boulton RA, Thim L, Hanby AM. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 108: 108-116, 1995.
26. Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA, Arnstein P. Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 58: 881-890, 1977.
27. Rigby CC, Franks LM. A human tissue culture cell line from a transi-tional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer 24: 746-754, 1970.
28. Saika T, Tsushima T, Nasu Y, Kumon H, Ohmori H. Epidermal growth factor in urine from patients with bladder cancer. Urol Res 28: 230-234, 2000.
29. Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 48: 424-431, 2005.
30. Sheng H, Shao J, Townsend CM Jr, Evers BM. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 52: 1472-1478, 2003.